Inclusion Criteria
Concurrent Medication:
Allowed:
Patients must have the following:
- Seropositive for HIV-1 (ELISA assay) confirmed by Western blot.
- HIV-1 p24 antigen must be detected in supernatant fluids from co-cultures of patients' PBMC on two separate occasions.
- Voluntarily sign consent.
- Patients with HIV "wasting syndrome" are allowed.
Prior Medication:
Allowed:
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
- AIDS as defined by the CDC.
- Significant hepatic disease.
- Thrombocytopenia.
- Hypersensitivity to thymopentin.
- Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products.
- Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry.
Patients with the following are excluded:
- AIDS as defined by the CDC.
- Significant hepatic disease.
- Thrombocytopenia.
- Hypersensitivity to thymopentin.
- Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products.
- Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry.
Prior Medication:
Excluded within 30 days of study entry:
- Immunomodulatory or experimental therapy.
- Excluded within 90 days of study entry:
- Zidovudine (AZT).
Intravenous drug abuse.